BioStack, a healthcare data startup with operations spanning the Americas and India, has raised $9.5 million in seed funding to build infrastructure that makes real-world patient data more accessible for research and drug development.
The round, announced on 26 October, was led by Peak XV Partners and Afore Capital. DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator also participated.
The company, founded by Sanat Mishra, operates in the United States, India, Brazil and Argentina and says it has access to more than 100 million de-identified patient records.
The Value of Real-World Data
Healthcare generates vast amounts of data, from electronic health records and laboratory results to imaging, prescriptions and insurance claims. Yet much of this information remains locked within individual hospitals and health systems, stored in incompatible formats and difficult for researchers to access.
Real-world data, information gathered from routine clinical care rather than controlled trials, has become increasingly important to pharmaceutical companies, researchers and regulators. It can help identify patients for clinical trials, track how treatments perform in diverse populations, detect safety signals and support regulatory submissions.
Regulators including the US Food and Drug Administration have issued frameworks for using real-world evidence in regulatory decisions, increasing demand for high-quality, well-structured datasets.
Why Geography Matters
BioStack's presence in India, Brazil and Argentina alongside the US is notable. Much of the world's medical research has historically relied on data from patients in North America and Europe, leaving populations in Asia, Latin America and Africa under-represented.
That imbalance matters because diseases, genetics, lifestyles and responses to treatment can vary across populations. Drugs and diagnostic tools developed using data from one population may not perform as well in others. Datasets that include patients from India and Latin America could help address those gaps.
India, with its large and diverse population and rapidly digitising health system, represents a significant opportunity. Government initiatives such as the Ayushman Bharat Digital Mission, which aims to create digital health records for citizens, are expanding the volume of structured health data available in the country.
Privacy at the Core
Working with patient data carries significant responsibilities. BioStack emphasises that its records are de-identified, meaning personal information that could identify individuals has been removed. Protecting privacy is essential to maintaining the trust of patients, hospitals and regulators.
Data protection rules vary across BioStack's markets. In the US, health data is governed by HIPAA. India's Digital Personal Data Protection Act introduces new obligations for how personal data is collected and processed, while Brazil's General Data Protection Law, known as LGPD, sets its own standards. Operating across these jurisdictions requires robust compliance systems and careful governance.
Investors With Deep Health and Tech Experience
The investor line-up brings a mix of experience. Peak XV Partners, formerly Sequoia Capital India and Southeast Asia, is one of the most active venture investors in India and has backed a range of healthcare and technology companies. Afore Capital is a US pre-seed and seed specialist.
DCVC, known for backing deep-tech companies including in computational biology and health, adds scientific credibility, while Emerson Collective, founded by Laurene Powell Jobs, invests across education, health and social impact. Y Combinator, the Silicon Valley accelerator, adds a network of founders and investors that can help early-stage companies win customers and future funding.
AI and the Data Opportunity
The rise of artificial intelligence has intensified interest in healthcare data. AI models used for diagnosis, drug discovery and clinical decision support require large, diverse, high-quality datasets to train and validate. Companies that can provide access to such data in a compliant way are becoming critical infrastructure for health AI.
Pharmaceutical companies are also using AI to accelerate drug development, from identifying targets to designing trials. Access to real-world data can help them understand disease progression, define patient populations and find participants for trials more efficiently.
Competitive Landscape
BioStack enters a market with established players. Companies such as IQVIA, Flatiron Health, owned by Roche, and Truveta, backed by major US health systems, have built large real-world data businesses, primarily focused on the US. Numerous startups are also building data platforms for specific diseases or regions.
BioStack's differentiation may lie in its multi-country footprint and focus on under-represented populations, which could appeal to pharmaceutical companies seeking global datasets for trials and regulatory submissions across markets.
The India Advantage
For India's health-tech sector, BioStack represents a different model from consumer-facing apps for consultations, pharmacy delivery or diagnostics. Infrastructure for health data and research is a less visible but potentially valuable segment, building on India's strengths in software engineering and data science.
India is also emerging as a significant destination for clinical trials, thanks to its large patient population, skilled medical workforce and lower costs. Better data infrastructure could strengthen India's position in global drug development.
From Data to Discovery
Real-world data platforms are increasingly used at every stage of drug development. Before trials begin, researchers analyse patient records to understand how diseases progress and which patient groups are most affected. During trial design, data can help identify sites with sufficient eligible patients and estimate how quickly recruitment can proceed. After approval, real-world evidence can be used to monitor safety and demonstrate value to payers and health systems.
Data from emerging markets could be especially useful as pharmaceutical companies expand trials beyond North America and Europe. Regulators have pressed for more diverse trial populations, and companies need to understand disease patterns and standards of care in countries where they plan to run studies or launch products. A platform with records from India, Brazil and Argentina alongside the US could help companies plan global development programmes more efficiently, provided data quality and consistency can be assured across very different health systems.
What Comes Next
With seed funding secured, BioStack will look to expand its data partnerships, build its platform and win customers among pharmaceutical companies, researchers and AI developers. Maintaining data quality and privacy across multiple countries will be essential.
The company's progress will be closely watched as an example of how healthcare data, once fragmented and underused, can become a foundation for faster, more inclusive medical research.
